简介:目的分析原发性眼眶肿瘤的组织来源、手术进路及手术效果。方法回顾性分析5年开眶手术治疗的眼眶肿瘤101例。结果前十位的眼眶肿瘤分别是:海绵状血管瘤22例(21.78%),静脉性血管瘤10例(9.9%),(表)皮样囊肿泪腺10例(9.9%),泪腺混合瘤8例(7.92%),炎性假瘤7例(6.93%),脑膜瘤6例(5.94%),腺样囊性癌5例(4.95%),淋巴瘤4例(3.96%),肉瘤3例(2.97%),神经鞘瘤2例(1.98%)。手术方法包括前路入眶68例,外侧开眶27例,眶内容6例,术后复发4例。结论开眶手术的术式选择与肿瘤的性质、位置、粘连情况、病变范围密切相关。术前对肿瘤的性质、位置、粘连程度的正确判断和手术操作技巧可减少术后复发等并发症。术后复发病例主要为脑膜瘤及泪腺肿瘤。
简介:目的观察自制全结膜囊羊膜固定器在重症眼表烧伤行羊膜遮盖手术中应用效果。方法在11例(13眼)眼部重症烫伤患者治疗中采用自制全结膜囊羊膜固定器将羊膜固定于眼表及眼睑皮肤面。根据病情需要更换羊膜,随访3月至3年。结果患者平均手术时间为(8.0±3.0)分钟;眼表组织上皮化时间(13.2±11.3)天。重复手术次数3.5次,患者手术依从性良好,观察病例无角膜穿孔,无睑球粘连。结膜囊狭窄5例,角膜斑翳5例,角膜血管化2例。结论采用自制全结膜囊羊膜固定器手术,缩短手术时间,无创伤,重症烧伤患者可多次重复手术,特别适合重症眼表烧伤早期治疗,减少晚期严重并发症的发生。
简介:目的观察上调白细胞介素10(IL-10)的表达对家兔慢性细菌性鼻窦炎动物模型上颌窦黏膜创伤修复的影响。方法以慢病毒(LV)为表达载体,上调IL-10的表达(LV-IL-10)。实验分3组:生理盐水注射组、LV-IL-10治疗组和LV-GFP注射组(GFP为绿色荧光蛋白)。制作家兔慢性细菌性鼻窦炎模型。在创伤前3d,各组上颌窦内侧壁黏膜下分别注射生理盐水、LV-IL-10和LV-GFP。于创伤后第3天和第10天取再生的上颌窦内侧壁黏膜,用实时聚合酶链反应和酶联免疫吸附试验分别在mRNA水平和蛋白水平检测相关细胞因子的表达。苏木素-伊红(HE)染色和Masson三染色法观察创伤后第10天再生黏膜的形态特征。结果在创伤后第3天和第10天再生的上颌窦黏膜中,LV-IL-10治疗组的胶原沉积明显减少,炎症反应较轻,且IL-6以及Ⅰ型和Ⅲ型胶原的mRNA表达水平明显下降。IL-6、IL-8以及Ⅰ型和Ⅲ型胶原的蛋白表达水平也明显下降,但3组间再生的上颌窦黏膜中转化生长因子β(TGF-β)mRNA的表达无明显差别。结论在家兔慢性细菌性鼻窦炎创伤修复的动物模型中,上调IL-10的表达可以抑制再生黏膜中的炎症反应,减少胶原沉积,改善再生黏膜的组织重塑。
简介:目的:探讨眼附属器B细胞非霍杰金淋巴瘤(B—cellnon-Hodgkinlymphoma,NHL)中Skp2,p27和PTEN的表达。方法:收集1995年到2011年青岛大学附属医院眼科石蜡包埋标本,用免疫组化法分别检测眼附属器B细胞NHL(n=30)标本中Skp2,p27和PTEN的表达,以眼部反应性淋巴组织增生(n=10)作为对照组。以患者的年龄、性别、发病部位,病理类型作为眼附属器B细胞NHL的的分类标准。结果:Skp2,p27和PTEN的表达与患者的年龄、性别、发病部位无关,而与病例类型有关。眼附属器B细胞NHLSkp2表达率与眼部反应性淋巴组织增生相比显著增高。p27,PTEN表达率与反应性淋巴组织增生相比显著降低。随眼附属器B细胞NHL病理分级的提高,Skp2的表达显著增高,p27和PTEN的表达显著降低。在黏膜相关淋巴组织结(mucosa—associatedlymphoidtissue,MALT)外边缘区B细胞淋巴瘤(diffuselargeB—celllymphoma,DLBCL)中,Skp2分别与p27,VFEN成负相关,p27和PTEN成正相关。结论:Skp2的表达升高,p27,PTEN蛋白的缺失以及可能与眼附属器B细胞NHL的发生有关;其中在MALT外边缘区DLBCL中,三种蛋白存在相关性。联合三种蛋白的检测眼附属器B细胞NHL的不同病理类型有重要意义。
简介:目的观察Ex-press青光眼引流器植入术治疗难治性青光眼患者的疗效及安全性。方法选取2015年月—520177月我院难治性青光眼患者74例(74眼),依据治疗方案不同分组,各37例(37眼)。观察组行Ex-press青光眼引流器植入术,对照组行小梁切除术。统计对比两组手术成功率及并发症发生情况。结果观察组手术成功率.49%(32/较对8637)照组59.46%(22/37)高,且并发症发生率18.92%(7/37)较对照组40.54%(15/37)低,差异有统计学意义(P〈0.05)。结论Ex-press青光眼引流器植入术应用于难治性青光眼治疗中,可进一步提高治疗效果,且安全性较高。
简介:AIM:Toinvestigatetheaccuracyofintraocularpressure(IOP)asmeasuredbyaReichertOcularResponseAnalyzer(ORA),aswellastherelationshipbetweencentralcornealthickness(CCT)andIOPasmeasuredbyORA,Goldmannapplanationtonometry(GAT),anddynamiccontourtonometry(DCT).·METHODS:Atotalof158healthyindividuals(296eyes)werechosenrandomlyformeasurementofIOP.AfterCCTwasmeasuredusingA-ultrasound(A-US),IOPwasmeasuredbyORA,GAT,andDCTdevicesinarandomizedorder.TheIOPvaluesacquiredusingeachofthethreetonometrieswerecompared,andtherelationshipbetweenCCTandIOPvalueswereanalyzedseparately.TwoIOPvalues,Goldmann-correlatedIOPvalue(IOPg)andcorneal-compensatedintraocularpressure(IOPcc),weregotusingORA.ThreegroupsweredefinedaccordingtoCCT:1)thincornea(CCT<520μm);2)normal-thicknesscornea(CCT:520-580μm);and3)thickcornea(CCT>580μm)groups.·RESULTS:Innormalsubjects,IOPmeasurementswere14.95±2.99mmHgwithORA(IOPg),15.21±2.77mmHgwithORA(IOPcc),15.22±2.77mmHgwithGAT,and15.49±2.56mmHgwithDCT.Meandifferenceswere0.01±2.29mmHgbetweenIOPccandGAT(P>0.05)and0.28±2.20mmHgbetweenIOPccandDC(P>0.05).TherewasagreatercorrelationbetweenIOPccandDCT(r=0.946,P=0.000)thanthatbetweenIOPccandGAT(r=0.845,P=0.000).DCThadasignificantcorrelationwithGAT(r=0.854,P=0.000).GATwasmoderatelycorrelatedwithCCT(r=0.296,P<0.001),whileIOPccshowedaweakbutsignificantcorrelationwithCCT(r=0.155,P=0.007).TherewasastrongnegativecorrelationbetweenCCTandthedifferencebetweenIOPccandGAT(r=-0.803,P=0.000),withevery10increaseinCCTresultinginanincreaseinthisdifferenceof0.35mmHg.Thethickcorneagroup(CCT>580μm)showedtheleastsignificantcorrelationbetweenIOPccandGAT(r=0.859,P=0.000);whilethethincorneagroup(CCT<520μm)hadthemostsignificantcorrelationbetweenIOPccandGAT(r=0.926,P=0.000).ThecorrelateddifferencesbetweenIOPccan
简介:AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra